A clear consequence of this study’s findings was that the standard-of-care chemotherapy drugs for neuroblastoma, many of which are known to require JNK to activate apoptosis, would lack efficacy in patient tumours with impaired JNK signalling. Here, MAPK8 is linked to neuroblastoma.